Data investigation
Normal Blood Sugar Is Not Remission
In a two-year trial against real-world care, 60.2% of people on tirzepatide reached an HbA1c below 5.7%. Every one of them was still taking the drug, and that distinction has a practical edge.
In a two-year trial, 60.2% of people taking tirzepatide reached an HbA1c below 5.7%, the non-diabetic range, against 24.0% of those receiving intensified conventional care.[1] That result is going to be described as reversing or curing diabetes. It is neither, for a reason that is not a technicality, and understanding why is the difference between a realistic plan and a painful surprise.
The comparator is what makes this trial unusual
Most trials in this field compare a drug against placebo, which answers a question nobody faces in a clinic. SURPASS-EARLY did something harder. It enrolled 794 adults across 78 sites in ten countries, all within four years of a type 2 diabetes diagnosis and all inadequately controlled on metformin, and randomized them to tirzepatide at 15 mg or the maximum they could tolerate, or to intensified conventional care: whatever their clinicians would otherwise do, guided by local treatment guidelines.
That comparison arm was allowed to include other GLP-1 receptor agonists. Only tirzepatide itself was excluded. So the trial set one drug against the realistic alternative, including its own closest competitors, rather than against nothing.
| Outcome | Tirzepatide | Conventional care | Difference |
|---|---|---|---|
| HbA1c change | −1.99 points (−2.12 to −1.87) | −1.32 points (−1.44 to −1.19) | −0.68 (−0.84 to −0.51), P<0.001 |
| Weight | — | — | −8.0 kg (−9.39 to −6.50), P<0.001 |
| Waist circumference | — | — | −6.2 cm (−7.54 to −4.93), P<0.001 |
| HbA1c below 5.7% | 60.2% | 24.0% | — |
Non-inferiority was the primary objective and superiority followed on every secondary measure tested. Gastrointestinal effects were the commonest adverse events in both arms, which is unsurprising when the comparison arm could also contain a GLP-1.
Why 'normoglycemia' is not remission
The distinction has a practical edge rather than a semantic one. A person told their diabetes is reversed may reasonably conclude the drug has done its job and can stop. What the evidence on stopping shows is that blood sugar returns to roughly where it started within 12 to 18 months (see stopping as a clinical transition).
A normal number on treatment describes the treatment working. It does not describe a condition that has gone.
None of this diminishes the result. Three in five people reaching the non-diabetic range at two years, against a quarter on the realistic alternative, is a large effect on a meaningful outcome. It is an argument for continuing a treatment rather than for having finished one.
What we cannot tell from the published account
The strength of the comparison depends on what the conventional-care arm actually received, and the published abstract does not say. Guidelines permitted GLP-1 receptor agonists in that arm; whether most participants got one, or mostly got sulfonylureas and insulin, changes how impressive a 0.68-point gap is.
We are not going to guess in either direction. If the comparison arm was largely GLP-1-treated, this is a striking result against a strong bar. If it was largely older agents, the bar was lower than the design suggests. The full trial report will say; the abstract does not.
- Open-label, which the authors list as their own limitation. It is also unavoidable, since you cannot blind an arm defined as “whatever the clinician chooses.”
- At most four years since diagnosis. This is early disease, where every agent performs best. Nothing here transfers to someone fifteen years in.
- Funded by Eli Lilly, who make tirzepatide. That is context, not disqualification, for a phase 4 trial in the Annals of Internal Medicine.
- Two years is long for this field and short for a lifelong condition. Durability past that point is not addressed.
Frequently Asked Questions
References
- 1.Del Prato S, Heine RJ, Pérez Manghi FC, et al. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial Annals of Internal Medicine. 2026. PMID: 42184419.
Compare the sellers
Related research
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
7 min read
How Many People to Treat to Help One
Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.
7 min read
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
7 min read
Tirzepatide in Ten- to Seventeen-Year-Olds
Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.
6 min read
Antipsychotics and Metabolic Harm
The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.
7 min read
A Quarter the Odds of Being Offered It
People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →